Pfizer announced a US$100 million investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. This expansion, which brings the total investment in the plant to US$372 million makes it one of the largest nutritional plants worldwide. 

The expansion of the plant to 91,963 square meters (the equivalent of 17 football fields) has boosted the plant’s production capacity by 50 percent and increased the plant’s ability to supply nutrition products to Singapore and key markets such as China, Indonesia, Malaysia, Pakistan, Sri Lanka, Thailand, Taiwan, Hong Kong and Vietnam. The Pfizer Singapore Nutritional Plant achieves sustainability through the use of advanced technology aimed at maximizing energy efficiency and reducing waste. Over 50 percent of water used by the plant for maintenance purposes is recycled.

“The expansion of our Singapore Nutrition Plant is one example of Pfizer’s commitment to securing a healthy and sustainable future for our children,” said Jeffrey B. Kindler, Chairman and Chief executive officer of Pfizer. “Our most valuable resources are our children and our environment, and Pfizer seeks to protect both by ensuring that our products for infants and children are manufactured to the most rigorous of safety and quality standards, with minimal environmental impact.”

“Infant Formula is one of the most stringently regulated consumer products in the world,” said Natale Ricciardi, Senior Vice President of Pfizer and President of Pfizer Global Manufacturing. “With about 120 colleagues working in Quality Operations alone, the plant maintains the highest quality and safety standards throughout every stage of the production process. Quality and compliance are critically important aspects of the Pfizer Global Manufacturing Culture.”